high expect new recent launch product
maintain hold rate unchang tp
provid upsid potenti
estim tp base forward price-to-earnings multipl
adjust ep compani
perform per expect wait watch
anoth quarter chang stanc
estim base follow factor double-digit
growth new recent launch product includ
repatha kyproli prolia xgeva strong product pipelin
expect launch
revenu increas
compar total product revenu
increas compar
total revenu
compar
total revenu prolia increas
total revenu xgeva increas
total revenu kyproli increas
revenu repatha increas
focus expans new product portfolio
expect launch aimovig
european launch amgevita
april announc plan build new next-
gener biomanufactur plant campu west
greenwich rhode island new plant employ next-
gener biomanufactur capabl manufactur
product global market
compani name inc tickeramgnstock ratingholdunchangedindustri viewoverweightpositivepric jun week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
net incom increas
compar non-gaap net incom
increas compar
gaap ep increas compar
non-gaap ep increas
compar
gener free cash flow
compar due higher net incom
declar dividend per share march
repurchas share
common stock total cost
guidanc total revenu expect rang
ep expect
rang non-gaap ep expect
rang non-gaap tax rate
expect rang capit
expenditur expect
stock price volatil past three year
averag price-to-earnings current trade
sinc past week
last quarter pe lower average pe
expect pe go higher
stock price movement volatil
quarter went low april
estim forward price-to-earnings multipl adjust
ep maintain rate hold
tp
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jun ex-dividend date may last split factor new per last split date inform amgen inc june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
incom statement item total gross research develop sell gener administr sg oper depreciation- oper profit interest incom net- special charges- interest incom minor interest- incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli inc june
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in capital- retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item amgen inc june
gener free cash flow compar
oper activ compar increas due
higher net incom higher accrual sale incent allow
invest activ compar increas
due activ relat market secur
financ activ compar cash use
due repurchas common stock payment dividend
depreciation- defer incom oper gains- increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate changes- net chang begin end inc june
first quarter perform strong due new recent
launch product deliv double-digit volume-driven growth
total revenu increas compar
total product revenu increas
compar total revenu
compar
increas
compar
gaap cog decreas compar
cog sale decreas pt
compar non-gaap cog
total product revenu decreas cog due lower
royalti lower amort intang asset partial off-set higher
increas pt
total product
revenu
compar
total product revenu
sg expens increas compar
sg expens total revenu
non-gaap sg expens compar
non-gaap sg expens total product
revenu increas sg expens due invest
product launch market product support
 expens decreas compar
 expens total revenu
non-gaap expens compar
non-gaap expens total product
revenu
oper expens decreas compar
non- oper expens
oper margin increas pt total product revenu
compar total product revenu non-gaap
oper margin total product revenu
interest expens compar
increas expens due impact increas interest rate
variable-r debt higher averag amount debt outstand
tax rate decreas pt compar
non-gaap tax rate decreas pt
compar decreas effect tax rate due
impact tax reform includ reduct statutori
tax rate partial off-set tax foreign earn
net incom increas compar
non-gaap net incom increas compar
gaap ep increas compar
non-gaap ep increas compar
gener free cash flow compar
due higher net incom declar dividend per share
march dividend paid june stockhold
record may repurchas share
common stock total cost
gaap ep increas
compar
increas
compar
increas
compar
princip product signific commerci sale
xgeva denosumab epogen also market number
etelcalcetid imlyg corlanor ivabradin
total product revenu increas compar
total product revenu
compar total product revenu rest world
increas compar
total revenu prolia increas
compar total revenu increas
compar total revenu
rest world increas compar
total revenu prolia
increas
compar
total revenu xgeva increas compar
total revenu increas
compar total revenu
rest world increas compar
total revenu kyproli increas
compar total revenu
rest world
total revenu parsabiv total revenu
rest world
increas revenu due launch product market
total revenu sensipar increas
compar total revenu
compar total revenu rest
world compar
total revenu repatha increas
compar total revenu increas
compar total revenu
rest world compar
total revenu
repatha increas
compar
total revenu nplate increas compar
total revenu
rest world
total revenu blyncyto increas
compar total revenu
rest world
total revenu increas compar
total revenu rest
world
total revenu neulasta decreas
compar total revenu
rest world decreas
due lower unit demand continu declin use
myelosuppress chemotherapi regimen favor prior year
chang account estim off-set partial favor chang net
sell price inventori
total revenu aranesp decreas
compar total revenu decreas
compar total revenu
rest world decreas compar
decreas due impact competit
total revenu epogen decreas
compar decreas due decreas net
sell price due contractu term negoti davita inc lower
total revenu
blyncyto increas
compar
total revenu
aranesp decreas
compar
total revenu decreas
compar total revenu
compar total revenu rest
world compar decreas
due impact competit unit demand
total revenu
decreas
compar
announc chmp
ema adopt
posit opinion includ
new indic
repatha label adult
total revenu enbrel decreas
compar total revenu
compar total revenu rest
world compar decreas
due lower unit demand lower net sell price favor prior
year chang account estim off-set partial favor chang
inventori
follow signific develop
affect compani busi
march announc committe medicin
product human use chmp european medicin agenc ema
adopt posit opinion includ new indic repatha label
adult establish atherosclerot cardiovascular diseas reduc
cardiovascular risk lower low-dens lipoprotein cholesterol level
recommend label recogn find repatha
research proprotein convertas subtilisin/kexin type
inhibit subject elev risk
announc chmp
ema issu
variat neulasta
includ neulasta
march announc fda approv acceler
approv supplement biolog licens applic blincyto
treatment adult children b-cell precursor acut
lymphoblast leukemia first second complet remiss minim
residu diseas greater equal
februari announc chmp ema issu
posit opinion recommend label variat neulasta includ
neulasta onpro kit
announc
approv expand
indic xgeva
prevent skeletal-
relat event patient
multipl myeloma
april announc european commiss approv
expand indic xgeva prevent skeletal-rel
event patient multipl myeloma
march announc chmp ema adopt
posit opinion market author applic kanjinti
biosimilar candid herceptin trastuzumab
kanjinti recommend approv treatment
three type cancer herceptin approv european
breast cancer metastat adenocarcinoma stomach
gastroesophag junction kanjinti develop
collabor allergan plc
april announc plan build new next-gener
biomanufactur plant campu west greenwich rhode island
new plant employ next-gener biomanufactur capabl
manufactur product global market
clinic programindicationproject milestoneskyprolisrelaps refractori multipl myelomaregulatori review os data blincytoacut lymphoblast leukemiaeu regulatori review tower os data proliaglucocorticoid-induc osteoporosisregulatori reviewseven romosozumab postmenopaus osteoporosisu regulatori resubmissioneu regulatori reviewaimovig erenumab migrain preventionregulatori biosimilar infliximab remicad inflammationphas dataabp trastuzumab herceptin oncologyregulatori review inc june
guidanc conclus
total revenu expect rang
gaap ep expect rang non-gaap
ep expect rang
non-gaap tax rate expect rang
capit expenditur expect
first-quart perform strong due new recent
launch product deliv double-digit volume-driven
revenu increas compar previou
year quarter total product revenu increas
compar previou year quarter due new recent
launch product includ repatha kyproli prolia xgeva show
plan expand new product portfolio
expect launch aimovig tm erenumab european
launch amgevita tm biosimilar adalimumab later
oper incom increas non- oper
incom increas oper margin increas pt
non-gaap oper margin decreas pt
gaap ep increas non-gaap ep increas
increas due combin reason higher product sale lower
tax rate lower weighted-averag share outstand
gener free cash flow compar
gaap ep expect
rang
non-gaap ep
expect
rang
plan
expand new
product portfolio
expect launch
european launch
adalimumab later
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin increas slightli ttm basi
oper margin ttm basi
net margin ttm basi
ep y/i ttm basi
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc june
mrqgross mrqoper mrqcog mrqsg mrqnet mrqr sale amgen inc june
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqreturn mrqreturn equiti amgen inc june
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item amgen inc june
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free inc june
stock price volatil past three year averag price-to-earnings current
trade sinc past week last quarter pe
lower average pe expect pe go higher
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form robert anthoni brian sean david jonathan vanc institut holdersholdershar report outvaluevanguard group inc fmr capit research global primecap manag northern trust morgan america top mutual fund holdersholdersharesd report outvaluevanguard total stock market invest compani vanguard/primecap vanguard spdr etf capit world growth incom vanguard institut fund-institut capit incom builder growth fund america amcap competit
develop receiv european commiss approv repatha evolocumab prevent heart attack stroke adult establish cardiovascular diseas announc theeuropean commiss ec approv new indic repatha evolocumab label adult establish atherosclerot cardiovascular diseas myocardi infarct stroke peripher arteri diseas reduc cardiovascular risk lower low-dens lipoprotein cholesterol ldl-c level expand label work payer ineuropeto remov prescrib barrier expand access order reach patient establish cardiovascular diseas risk anoth event receiv posit chmp opinion expand use prolia denosumab patient glucocorticoid-induc osteoporosi announc committe medicin product human use chmp theeuropean medicin agenc ema adopt posit opinion market author prolia denosumab treatment bone loss associ long-term system glucocorticoid therapi adult patient increas risk fractur present first-of-its-kind data annual meet reinforc robust consist efficaci aimovig erenumab migrain patient multipl treatment failur announc full result phase liberti trial aimovig erenumab episod migrain patient previous fail two four prevent treatment due lack efficaci intoler side effect data present meet theamerican academi neurolog inlo angel show potenti aimovig effect prevent treatment option patient tri sever treatment option without gain relief aimovig investig fulli human monoclon antibodi regulatori review design select block calcitonin gene-rel peptid cgrp receptor play critic role migrain activ allergan receiv posit chmp opinion abp biosimilar herceptin treatment three type cancer andallergan plc announc thecommitte medicin product human use chmp theeuropean medicin agenc ema adopt posit opinion market author abp biosimilar herceptin trastuzumab abp recommend approv treatment three type cancer includ metastat breast cancer earli breast cancer metastat adenocarcinoma stomach gastroesophag junction may inc june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
compar
ttm
compar
oper margin ttm
 industri
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc june
consensu view analyst trend stock
forecast
forecast
forward price-to-earnings
less compar
stock current
under-valued price-to-earnings
industri average
amgn avgfive-year growth forecast usdgrowth high day day day estim comparisonamgnindustri avg avgprice/earn yield inc june
consensu view analyst trend stock
averag earn estim current
qtr jun next
qtr sep
sale growth estim current qtr
jun next qtr
sep
averag revenu estim current
qtr jun
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr amgen inc june
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
stock perform volatil quarter went low april
stock given flat return quarter trade around may
annual perform stock show increas trend huge fluctuat one year
stock reach fresh high given total return last year
stock trade jun reach may given
return past year stock volatil past year
first quarter perform strong due new recent launch product upgrad
rate buy base perform expect launch maintain tp
base price-to-earnings multipl estim ep
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
